Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of the Perihilar Cholangiocarcinoma Risk Estimation of Tumor Recurrence After Transplant (PRETREAT) Score.

Annals of surgery·2025
Same author

Differential MYC Phosphorylation Drives the Divergent Cholangiocyte Response to Stress.

Cellular and molecular gastroenterology and hepatology·2025
Same author

Deep learning-based uncertainty quantification for quality assurance in hepatobiliary imaging-based techniques.

Oncotarget·2025
Same author

Deep learning analysis of MRI accurately detects early-stage perihilar cholangiocarcinoma in patients with primary sclerosing cholangitis.

Hepatology (Baltimore, Md.)·2025
Same author

The dynamic landscape of cholestatic liver disease.

Hepatology (Baltimore, Md.)·2025
Same author

Aptamer-directed, nanovesicle-mediated targeting of undruggable molecules in preclinical cholangiocarcinoma models.

Hepatology (Baltimore, Md.)·2025
Same journal

Orosomucoid 2 as an immunometabolic regulator in cardiometabolic disease: Molecular mechanisms and translational potential.

Biochimica et biophysica acta. Molecular basis of disease·2026
Same journal

In vivo dysregulation of insulin and glucagon secretion: Disturbed mitochonderial VDAC1 expression and localization in pancreatic β-cells convey global insulin secretory defects in diabetic GK rat.

Biochimica et biophysica acta. Molecular basis of disease·2026
Same journal

B3GNT2 promotes gastric cancer metastasis by facilitating membrane trafficking of RYK via N-glycosylation.

Biochimica et biophysica acta. Molecular basis of disease·2026
Same journal

An AAV-based bioluminescent reporter reveals dynamic YAP/TAZ-TEAD transcriptional activity during liver injury.

Biochimica et biophysica acta. Molecular basis of disease·2026
Same journal

Small-molecule LIFR inhibitors attenuate renal tubulointerstitial fibrosis.

Biochimica et biophysica acta. Molecular basis of disease·2026
Same journal

Early melatonin supplementation partially delays gastrointestinal aging.

Biochimica et biophysica acta. Molecular basis of disease·2026
See all related articles

Related Experiment Video

Updated: Feb 24, 2026

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb
04:50

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb

Published on: January 17, 2025

871

Targeting cholangiocarcinoma.

Joachim C Mertens1, Sumera I Ilyas2, Gregory J Gores2

  • 1Department of Gastroenterology and Hepatology, University Hospital Zürich, Switzerland.

Biochimica Et Biophysica Acta. Molecular Basis of Disease
|August 29, 2017
PubMed
Summary
This summary is machine-generated.

Cholangiocarcinoma (CCA) exhibits molecular diversity, challenging targeted therapies. Combinations of targeted agents with tumor microenvironment treatments show promise for this biliary tract cancer.

Keywords:
Biliary tract cancerCholangiocarcinomaDriver mutationsMicroenvironmentMolecular targets

More Related Videos

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

10.8K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

6.2K

Related Experiment Videos

Last Updated: Feb 24, 2026

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb
04:50

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb

Published on: January 17, 2025

871
Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

10.8K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

6.2K

Area of Science:

  • Oncology
  • Gastroenterology
  • Molecular Biology

Background:

  • Cholangiocarcinoma (CCA) is a diverse biliary tract cancer with distinct anatomical (intrahepatic, perihilar, distal) and molecular subtypes.
  • Specific genetic aberrations like IDH mutations and FGFR2 fusions characterize intrahepatic CCA (iCCA), while KRAS mutations and PRKACB fusions are found in perihilar (pCCA) and distal (dCCA) CCA.
  • The molecular heterogeneity of CCA, as highlighted by TCGA, complicates the widespread use of targeted therapies.

Purpose of the Study:

  • To review the molecular landscape of cholangiocarcinoma.
  • To discuss the challenges posed by CCA's heterogeneity for targeted therapy development.
  • To explore the potential of targeting the tumor microenvironment and combinatorial treatment strategies.

Main Methods:

  • Review of molecular profiling data from The Cancer Genome Atlas (TCGA) for CCA.
  • Analysis of genetic aberrations associated with different anatomical subsets of CCA.
  • Discussion of potential therapeutic strategies targeting tumor microenvironment components.

Main Results:

  • Identification of distinct molecular drivers for iCCA, pCCA, and dCCA.
  • Acknowledgement of significant molecular heterogeneity across CCA subtypes.
  • Highlighting the potential of targeting cancer-associated fibroblasts and T-cell exhaustion.

Conclusions:

  • CCA's molecular diversity necessitates personalized treatment approaches.
  • Targeting the tumor microenvironment, alongside specific genetic aberrations, offers a promising avenue for advancing CCA treatment.
  • Combinatorial therapies hold potential for improving outcomes in this devastating malignancy.